Cure My Disease

Don't miss your cure!

 Log in / Sign up

Quick shot or slow drip? study tests best way to give oxytocin to prevent bleeding in C-Sections

NCT ID NCT07688512

Disease control Sponsor: Stony Brook University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This study compares giving oxytocin as a single quick injection (bolus) versus a slow drip (infusion) during planned cesarean sections in mothers at high risk for heavy bleeding. The goal is to see which method achieves better uterine tightening faster and with fewer side effects. Researchers will also measure blood loss and patient satisfaction. The findings could help standardize care to prevent postpartum hemorrhage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Oxytocin
What this could lead to
If one method proves better, it could reduce bleeding and side effects during cesarean sections for high-risk mothers.
What could go wrong
This is a single-center Phase 4 trial with 180 participants, so results may not apply broadly. Both methods are already standard care, so dramatic differences are unlikely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Undergoing elective cesarean section under spinal anesthesia or combined spinal anesthesia (CSE) * Patients must be able to provide written informed consent in either English or Spanish * Parturient classified as high risk for postpartum hemorrhage as defined by the adapted California Maternal Quality Care Obstetric Hemorrhage Risk Screen Exclusion Criteria: * Parturient in labor or ruptured membranes * Patient does not possess the physical and mental capacity to provide informed consent * Urgent or emergent cesarean sections * Patients with a known major coagulopathy * Patients with significant thrombocytopenia limiting neuraxial anesthesia (\<70k) * Patients on therapeutic anticoagulation at time of procedure * Patients on the placenta accreta spectrum * Patients with severe cardiac disease contraindicating oxytocin * Patients with an allergy to oxytocin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Elective cesarean section are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Postpartum Hemorrhage Uterine Inertia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Elective cesarean section Postpartum hemorrhage Uterine atony Uterine atony with hemorrhage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.